Внутрикорпоративная торговля на американском рынке | Royalty Pharma раскрыла 4 сделки внутреннего трейдинга 4 марта

K-LinePoet · 2026-03-29T17:57:18+00:00

4 марта 2026 года Royalty Pharma сообщил, что руководитель Coyne Terrance P. 2 марта совершил несколько продаж акций на сумму более 1,04 миллиона юаней, что отражает торговую активность инсайдеров.

K-LinePoet

2026-03-29 17:57:18

Генерация тезисов в процессе

4 March 2026, Royalty Pharma（RPRX） disclosed 4 insider transactions by company insiders. Executive Coyne Terrance P. sold 22,500 shares on 2 March 2026.

【Recent Insider Trades】

Disclosure date	Position	Name	Trade date	Buy/Sell	Quantity	Execution price per share/US Dollar	Total amount/US Dollar
4 March 2026	Executive	Coyne Terrance P.	2 March 2026	Sold	1292	46.67	60,300
4 March 2026	Executive	Coyne Terrance P.	2 March 2026	Sold	583	47.01	27,400
4 March 2026	Executive	Coyne Terrance P.	2 March 2026	Sold	22,500	46.67	10.495 million
4 March 2026	Executive	Coyne Terrance P.	2 March 2026	Sold	10,400	47.01	490,300
25 February 2026	Executive	Coyne Terrance P.	23 February 2026	Sold	34,800	45.32	1.5766 million
4 February 2026	Executive	Coyne Terrance P.	3 February 2026	Sold	6195	42.84	265,400
4 February 2026	Executive	Coyne Terrance P.	3 February 2026	Sold	108,800	42.84	4.6596 million
4 February 2026	Executive	Coyne Terrance P.	2 February 2026	Sold	108,400	42.08	4.5629 million
4 February 2026	Executive	Coyne Terrance P.	4 February 2026	Sold	20,200	43.29	872,900
2 February 2026	Executive	Urist Marshall	30 January 2026	Sold	20,000	41.09	821,800

【Company Profile】

Royalty Pharma plc was incorporated on 6 February 2020 under the laws of England and Wales. The company is the largest buyer of bio-pharmaceutical royalties and a major funder of innovation in the bio-pharmaceutical industry. Since its founding in 1996, the company has been a pioneer in the royalties market, partnering with innovators from academic institutions, research hospitals, and non-profit organizations (from small and medium-sized biotechnology companies to leading global pharmaceutical companies). The company collects a range of royalties, giving it the right to make payments directly based on top-line sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri, and Xtandi. The company directly or indirectly provides funding for innovation in the bio-pharmaceutical industry, when they jointly fund later-stage clinical trials and product launches with companies in exchange for future royalties, and when they receive existing royalties from the original innovators.

Посмотреть Оригинал

На этой странице может содержаться сторонний контент, который предоставляется исключительно в информационных целях (не в качестве заявлений/гарантий) и не должен рассматриваться как поддержка взглядов компании Gate или как финансовый или профессиональный совет. Подробности смотрите в разделе «Отказ от ответственности» .

2 Лайков